Literature DB >> 25243539

Perfusion CT for selecting patients with acute ischemic stroke for intravenous thrombolytic therapy.

Kirsteen R Burton1, Deljit Dhanoa, Richard I Aviv, Alan R Moody, Moira K Kapral, Andreas Laupacis.   

Abstract

PURPOSE: To determine rates of death, disability, and symptomatic intracranial hemorrhage ( SICH symptomatic ICH ) among patients with acute ischemic stroke selected for thrombolytic therapy by using perfusion computed tomography (CT) by conducting a systematic review and meta-analysis.
MATERIALS AND METHODS: A search of the literature up to July 2012 was performed by using MEDLINE, EMBASE, the Cochrane Library, PubMed, and Google Scholar on terms including "brain ischemia" and "perfusion imaging." The search was unrestricted by language of publication. Two reviewers extracted study data and independently assessed the risk of study bias. Outcomes of patients selected by using perfusion CT, including case-fatality rate, favorable outcome (modified Rankin Scale [ mRS modified Rankin Scale ] score, ≤2), and rates of SICH symptomatic ICH , were estimated.
RESULTS: Thirteen experimental or observational studies that included patients who received intravenous thrombolytic treatment after perfusion CT were identified. The methodologic quality of the small studies was generally good. Overall, 90-day mortality was 10.0% (95% confidence interval [ CI confidence interval ]: 5.4%, 15.9%). Among patients treated within 3 hours of symptom onset, mortality was 12.5% (95% CI confidence interval : 6.7%, 19.7%), a favorable outcome ( mRS modified Rankin Scale score, ≤2) was seen in 42.5% of patients (95% CI confidence interval : 16.6%, 70.9%), and the SICH symptomatic ICH rate was 3.3% (95% CI confidence interval : 0.7%, 7.7%). Among patients treated more than 3 hours after symptom onset, mortality was 2.9% (95% CI confidence interval : 0.0%, 12.7%), 69.9% of patients (95% CI confidence interval : 0%, 83.5%) had a favorable outcome, and the SICH symptomatic ICH rate was 3.9% (95% CI confidence interval : 0.8%, 9.2%).
CONCLUSION: The outcomes (mortality, morbidity, and SICH symptomatic ICH rates) for patients selected with perfusion CT to receive intravenous thrombolytic treatment more than 3 hours after symptom onset appear favorable.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25243539     DOI: 10.1148/radiol.14140728

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  6 in total

1.  The Curved MCA: Influence of Vessel Anatomy on Recanalization Results of Mechanical Thrombectomy after Acute Ischemic Stroke.

Authors:  B J Schwaiger; A S Gersing; C Zimmer; S Prothmann
Journal:  AJNR Am J Neuroradiol       Date:  2015-01-29       Impact factor: 3.825

2.  Optimal Computed Tomographic Perfusion Scan Duration for Assessment of Acute Stroke Lesion Volumes.

Authors:  Aimen S Kasasbeh; Søren Christensen; Matus Straka; Nishant Mishra; Michael Mlynash; Roland Bammer; Gregory W Albers; Maarten G Lansberg
Journal:  Stroke       Date:  2016-11-15       Impact factor: 7.914

Review 3.  The Next Step in the Treatment of Stroke.

Authors:  Nathanael Matei; Justin Camara; John H Zhang
Journal:  Front Neurol       Date:  2021-01-22       Impact factor: 4.003

4.  Study on Model Iterative Reconstruction Algorithm vs. Filter Back Projection Algorithm for Diagnosis of Acute Cerebral Infarction Using CT Images.

Authors:  Songlin Tang; Yan Liu; Zhifu Wang; Yajie Liu; Huafei Liu
Journal:  J Healthc Eng       Date:  2021-08-05       Impact factor: 2.682

5.  Influence of Thin Slice Reconstruction on CT Brain Perfusion Analysis.

Authors:  Edwin Bennink; Jaap Oosterbroek; Alexander D Horsch; Jan Willem Dankbaar; Birgitta K Velthuis; Max A Viergever; Hugo W A M de Jong
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240

6.  A prospective development study of software-guided radio-frequency ablation of primary and secondary liver tumors: Clinical intervention modelling, planning and proof for ablation cancer treatment (ClinicIMPPACT).

Authors:  Martin Reinhardt; Philipp Brandmaier; Daniel Seider; Marina Kolesnik; Sjoerd Jenniskens; Roberto Blanco Sequeiros; Martin Eibisberger; Philip Voglreiter; Ronan Flanagan; Panchatcharam Mariappan; Harald Busse; Michael Moche
Journal:  Contemp Clin Trials Commun       Date:  2017-08-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.